Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNC Drug Makers Say Pakistan Policies Discourage Branded-Drug Entry

This article was originally published in PharmAsia News

Executive Summary

A drug-maker group in Pakistan blamed local challenges to intellectual property rights for the failure of many international branded drugs to reach the nation’s market.

You may also be interested in...



FDA Releases COVID-19 Test Performance Data

The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.

SERB Pays $800m For Boston Scientific Specialty Pharma Business

The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.

SUNSET Draft Rule Is Trump Admin’s ‘Latest Attempt To Sabotage HHS Programs,’ Analyst Charges

The proposed rule from the US HHS that would require its agencies to review all regulations every 10 years could distract an incoming Biden administration from the COVID-19 pandemic and will “wreak havoc” on Medicare, a senior policy analyst for the Center on Budget and Policy Priorities says.

Topics

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel